Detalles de la búsqueda
1.
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Mult Scler;
23(6): 818-829, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27503905
2.
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
Clin Kidney J;
16(4): 701-710, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37007688
3.
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
Mult Scler J Exp Transl Clin;
7(4): 20552173211061550, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34925876
4.
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.
Neurol Neuroimmunol Neuroinflamm;
4(2): e327, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28210662
5.
Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.
Expert Opin Drug Saf;
16(2): 247-255, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27989217
6.
Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.
Clin Exp Neuroimmunol;
8(2): 129-137, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28706565
7.
The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study.
J Neuroimaging;
27(1): 97-106, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27214389
Resultados
1 -
7
de 7
1
Próxima >
>>